Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2018

01-02-2018 | Breast Oncology

Molecular Genomic Testing for Breast Cancer: Utility for Surgeons

Authors: Oluwadamilola M. Fayanju, MD, MA, MPHS, Ko Un Park, MD, Anthony Lucci, MD, FACS

Published in: Annals of Surgical Oncology | Issue 2/2018

Login to get access

Abstract

Molecular genomic testing provides clinicians with both prognostic and (sometimes) predictive information that can help individualize treatment and decrease the risk of over- or under-treatment. We review the genomic tests that are currently available for clinical use in management of breast cancer, discuss ongoing research related to validating and expanding their utility in different patient populations, and explain why it is important for surgeons to know how to incorporate these tools into their clinical practice in order to individualize patient treatment, reduce unnecessary morbidity, and, accordingly, improve outcomes.
Literature
1.
Joh JE, Esposito NN, Kiluk JV, et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist. 2011;16:1520–1526.CrossRefPubMedPubMedCentral
2.
Paik S, Shak S, Tang G, et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients–NSABP studies B-20 and B-14. Breast Cancer Res Treat. 2003;82:A16.
3.
Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11:8623–8631.CrossRefPubMed
4.
Esteban J, Baker J, Cronin M, et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol. 2003;22:850.
5.
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826.CrossRefPubMed
6.
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734.CrossRefPubMed
7.
Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152:389–398.CrossRefPubMedPubMedCentral
8.
Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–710.CrossRefPubMedPubMedCentral
9.
10.
Gluz O, Nitz UA, Christgen M, et al. West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34(20): 2341–2349.CrossRefPubMed
11.
AJCC Cancer Staging Manual. Springer, New York; 2017.
12.
Hayes DF. Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol. 2012;30:1264–1267.CrossRefPubMed
13.
Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.CrossRefPubMed
14.
Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–3696.CrossRefPubMed
15.
Zanotti L, Bottini A, Rossi C, et al. Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. Tumor Biol. 2014;35:8461–8470.CrossRef
16.
Dabbs DJ, Klein ME, Mohsin SK, et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011;29:4279–4285.CrossRefPubMed
17.
Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1049–1060.CrossRefPubMed
18.
Yardley DA, Peacock NW, Shastry M, et al. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Res Treat. 2015;154:299–308.CrossRefPubMed
19.
Bear HD, Wan W, Robidoux A, et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. J Surg Oncol. 2017;115:917–923.CrossRefPubMed
20.
Shak S, Petkov V, Miller D, et al. Abstract P5-15-01: breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and oncotype DX recurrence score results in the SEER database. Cancer Res. 2016;76:P5–P15.CrossRef
21.
Stemmer S, Steiner M, Rizel S, et al. Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤ 30 is > 98%. Cancer Res. 2016;76:P5–08.CrossRef
22.
Mook S, Veer L, Rutgers EJT, et al. Individualization of therapy using Mammaprint®ì: from development to the MINDACT Trial. Cancer Genom Proteom. 2007;4:147–155.PubMed
23.
van de Vijver MJ, He YD, van ‘t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.CrossRefPubMed
24.
Cardoso F, Piccart-Gebhart M, Van’t Veer L, Rutgers E. The MINDACT trial: The first prospective clinical validation of a genomic tool. Mol Oncol. 2007;1:246–251.CrossRefPubMedPubMedCentral
25.
Liu J. Model Selection/Validation. In: Cosmatos D, Chow S-C (eds) Translational medicine: strategies and statistical methods. Boca Raton, FL: Chapman and Hall/CRC, Taylor & Francis Group; 2009.
26.
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–729.CrossRefPubMed
27.
Drukker CA, Bueno-de-Mesquita JM, Retèl VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013;133:929–936.CrossRefPubMedPubMedCentral
28.
Bartlett JM, Thomas J, Ross DT, et al. Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010;12:1–11.
29.
Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:1.CrossRef
30.
Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008;14:2601–2608.CrossRefPubMed
31.
Link JS, Buck LJ, Kapoor NS. The breast cancer index as a tool in decision making for adjuvant hormonal therapy in early luminal breast cancer: Initiation, withdrawal and continuance. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8–12. Cancer Res. 2016;72: Abstract nr P5-08-10.
32.
Dubsky P, Filipits M, Jakesz R, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;24:640–647.CrossRefPubMed
33.
34.
Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009;27:3185–3191.CrossRefPubMedPubMedCentral
35.
Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–4278.CrossRefPubMed
36.
Bartlett JM, Bayani J, Marshall A, et al. Comparing breast cancer multiparameter tests in the OPTIMA Prelim trial: no test is more equal than the others. J Natl Cancer Inst. 2016;108:djw050.CrossRef
37.
38.
Rakha EA, Soria D, Green AR, et al. Nottingham prognostic index plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer. 2014;110:1688–1697.CrossRefPubMedPubMedCentral
39.
Green AR, Soria D, Stephen J, et al. Nottingham prognostic index plus: validation of a clinical decision making tool in breast cancer in an independent series. J Pathol Clin Res. 2016;2:32–40.CrossRefPubMedPubMedCentral
40.
Sinn P, Aulmann S, Wirtz R, et al. Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility. Geburtshilfe Frauenheilkd. 2013;73:932–940.CrossRefPubMedPubMedCentral
41.
D’Alfonso TM, van Laar RK, Vahdat LT, et al. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence. Breast Cancer Res Treat. 2013;139:705–715.CrossRefPubMed
42.
Tutt A, Wang A, Rowland C, et al. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer. 2008;8:339.CrossRefPubMedPubMedCentral
Metadata
Title
Molecular Genomic Testing for Breast Cancer: Utility for Surgeons
Authors
Oluwadamilola M. Fayanju, MD, MA, MPHS
Ko Un Park, MD
Anthony Lucci, MD, FACS
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6254-z

Other articles of this Issue 2/2018

Annals of Surgical Oncology 2/2018 Go to the issue

Colorectal Cancer

Treatment and Outcome of Synchronous Colorectal Carcinomas: A Nationwide Study

Bone and Soft Tissue Sarcomas

Amputation for Sarcoma: Revisiting a 19th Century Treatment in the 21st Century

Thoracic Oncology

Impact of Sarcopenia on Unplanned Readmission and Survival After Esophagectomy in Patients with Esophageal Cancer

Health Services Research and Global Oncology

Precision Medicine Core: Progress in Prognostication—Populations to Patients

Melanomas

Use of a Purse-String Suture to Reduce Skin Graft Requirements

Gastrointestinal Oncology

A Novel Preoperative Skeletal Muscle Measure as a Predictor of Postoperative Complications, Long-Term Survival and Tumor Recurrence for Patients with Gastric Cancer After Radical Gastrectomy